Henri B. Kagan of France and Kenso Soai of Japan received the 2026 Nobel Prize in Chemistry for discoveries involving nonlinear effects and autocatalysis in asymmetric organic synthesis, according to both Brazilian reports. Their work addresses homo-chirality: the tendency of living systems to use one of two otherwise mirror-image molecular forms.¹

The Brazil Left account frames the prize primarily through its implications for medicine. It notes that many drug molecules have two non-identical mirror forms, where one may provide the therapeutic benefit while the other can bring unnecessary, and sometimes harmful, side effects. The Nobel Committee said the scientists’ findings were decisive for chemists developing reactions for pharmaceuticals.¹ In that telling, the research is fundamental chemistry with an unusually direct route to safer and more precise products.

The Brazil Right report reaches the same conclusion about the importance of molecular selectivity, but puts more emphasis on how the breakthrough unfolded. It describes Kagan’s 1986 work as a decisive advance in producing a larger-than-expected excess of one mirror-image form. Soai then designed a reaction with the potential to become homo-chiral in 1995 and, in 2003, demonstrated one that formed only one of the two possible mirror images.²

That account broadens the practical picture beyond pharmaceuticals, identifying aromas, fragrances, agricultural chemicals and new materials as areas affected by the discoveries.² The two reports therefore differ more in focus than substance: one highlights why selecting the right molecular “hand” matters for treatments, while the other charts the experimental route that gave chemists tools to make that selection.

For Soai, the announcement was also personal: “This is the most exciting day of my life; I am very happy to share this prize with Professor Henri Kagan.”¹